Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. Company
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Number of employees : 3 082 people.
Sales per Business
20202021Delta
Immunotherapy Technologies549.84100%22 430.10100% +3979.4%
USD in Million
Sales per region
20202021Delta
Germany549.84100%22 430.10100% +3979.4%
USD in Million
Managers
Name Title Age Since
Ugur Sahin Chief Executive Officer 56 2008
Jens Holstein Chief Financial Officer 57 2021
Özlem Türeci Chief Medical Officer 54 2018
Sierk Pötting Chief Operating Officer 48 2021
Sylke Maas, Dr. VP-Investor Relations & Business Strategy - -
Sean Marett Chief Business & Commercial Officer 56 2012
Ryan Richardson Senior VP-Corporate Development & Strategy 54 2018
Members of the board
Name Title Age Since
Helmut Jeggle Chairman-Supervisory Board 51 2008
Christoph Huber, Dr. Member-Supervisory Board 77 2008
Michael Motschmann Member-Supervisory Board 64 2008
Ulrich Wandschneider, Dr. Member-Supervisory Board 61 2018
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 246,310,081 214,949,219 87.3% 3,788,592 1.5% 87.3%
Shareholders
NameEquities%
Baillie Gifford & Co. 6,744,697 2.73%
PRIMECAP Management Co. 4,242,068 1.72%
J.O. Hambro Capital Management Ltd. 1,957,594 0.79%
Flossbach von Storch AG 1,920,089 0.78%
BlackRock Fund Advisors 1,569,281 0.64%
T. Rowe Price Associates, Inc. (Investment Management) 1,526,825 0.62%
Fidelity Management & Research Co. LLC 1,195,323 0.48%
Shanghai Fosun Industry Investment Co., Ltd. 1,053,640 0.43%
Invus Public Equities Advisors LLC 900,000 0.36%
Capital Research & Management Co. (World Investors) 744,322 0.30%
Company contact information
BioNTech SE
An der Goldgrube 12
Mainz, Rheinland-Pfalz 55131

Phone : +49.6131.9084.0
Web : http://www.biontech.de
Brand Portfolio
In partnership withAllbrands.markets
More brands of BioNTech SE
Analysis
Zoom Video Communications, Inc.: An attempt to reconnect
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
BIONTECH SE-38.65%38 433
GILEAD SCIENCES, INC.-11.21%81 543
REGENERON PHARMACEUTICALS, INC.8.22%74 440
VERTEX PHARMACEUTICALS22.79%69 269
WUXI APPTEC CO., LTD.-25.70%39 423
GENMAB A/S-19.73%19 850
ARGENX SE-6.85%17 140
BEIGENE, LTD.-51.55%13 146
NEUROCRINE BIOSCIENCES, INC.5.48%8 447
HALOZYME THERAPEUTICS, INC.15.12%6 378
LEGEND BIOTECH CORPORATION-15.58%6 040
SAREPTA THERAPEUTICS, INC.-21.27%5 993
EXELIXIS, INC.-0.49%5 712
INTRA-CELLULAR THERAPIES, INC.12.19%5 345
ASCENDIS PHARMA A/S-32.88%5 039
BIOCON LIMITED-11.09%4 972
MARAVAI LIFESCIENCES HOLDINGS, INC.-18.35%4 500
CEREVEL THERAPEUTICS HOLDINGS, INC.-17.00%3 990
ARROWHEAD PHARMACEUTICALS, INC.-49.73%3 592
PHARMAESSENTIA CORPORATION17.58%3 394
CYTOKINETICS, INCORPORATED-14.46%3 319
Connections : BioNTech SE